Curiox Biosystems Hits Record Highs... Leading Technology for Global Standardization

Kiwoom Securities Estimates 14.1 Billion KRW Operating Loss for Curiox This Year
Share Price Up 177% Year-to-Date
New Market Opportunities Expected on the Back of Advanced Technology

The share price of Curiox Biosystems has surged significantly this year. Despite expectations of a large operating loss again this year, the company's corporate value is rising on the back of strong growth prospects.

According to the financial investment industry on August 14, Curiox Biosystems' stock has risen by 177% so far this year. On August 12, it reached an all-time high of 53,800 won during intraday trading.

Individual investors have purchased 21.3 billion won worth of Curiox Biosystems shares this year. The average purchase price per share was 26,567 won, resulting in an evaluated return rate of 93.5%. Institutional investors, on the other hand, recorded a cumulative net sale of 32.8 billion won.

Curiox Biosystems succeeded in automating the cell analysis process for the first time in the world and commercialized technology to improve reproducibility. The company also participated in the cell analysis standardization consortium of the U.S. National Institute of Standards and Technology (NIST).

As precision medicine and personalized medicine advance, automation, data accuracy, and reproducibility are becoming increasingly important. The cell analysis process can largely be divided into two stages: staining cells in their natural state and reading the stained cells with a device. The process of reading stained cells has already been fully automated. In contrast, the staining process is still conducted manually using a centrifuge, which leads to variations in data quality depending on the researcher's level of expertise.

Curiox Biosystems aims to lead the field by developing automated products that could become the global standard in cell analysis. Lee Geonjae, a researcher at IBK Investment & Securities, stated, "The traditional manual method using a centrifuge is not efficient in terms of cost and time," adding, "Curiox Biosystems' technology is highly likely to be actively utilized in the cell therapy and gene therapy markets."

With the market on the verge of opening up, Curiox Biosystems' corporate value is rising as it secures the most advanced technology. The company's market capitalization has surpassed 830 billion won, reflecting a high valuation relative to its sales scale. Kiwoom Securities estimates that Curiox Biosystems will record sales of 5.3 billion won and an operating loss of 14.1 billion won this year. Sales are expected to increase by 16.0% compared to last year, while the operating loss is projected to widen. Shin Minsu, a researcher at Kiwoom Securities, explained, "In June last year, Curiox Biosystems launched the 'Pluto LT' device, which offers essential functions at a lower price point. The previous Lamina Wash series struggled to penetrate the market due to its high price."

He added, "Following last year, the company also participated in the cell-based research society (CYTO) again this year," and noted, "Global pharmaceutical company AstraZeneca announced that it improved reproducibility after adopting Curiox Biosystems' equipment."

This content was produced with the assistance of AI translation services.